Paula Marlton
Overview
Explore the profile of Paula Marlton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iland H, Reynolds J, Boddy A, Schultz H, Khoo L, Fleming S, et al.
Blood Adv
. 2025 Jan;
PMID: 39874494
The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily...
2.
Neller M, Ambalathingal G, Hamad N, Sasadeusz J, Pearson R, Holmes-Liew C, et al.
Nat Commun
. 2024 Dec;
15(1):10339.
PMID: 39627190
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19...
3.
Yuen S, Phillips T, Bannerji R, Marlton P, Gritti G, Seymour J, et al.
Am J Hematol
. 2024 May;
99(7):1281-1289.
PMID: 38700035
The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed-dose obinutuzumab 1000 mg or rituximab 375 mg/m in...
4.
Tiong I, Wall M, Bajel A, Kalro A, Fleming S, Roberts A, et al.
Blood Cancer J
. 2024 Mar;
14(1):54.
PMID: 38531863
Despite an increasing desire to use historical cohorts as "synthetic" controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental...
5.
Tam C, Opat S, DSa S, Jurczak W, Lee H, Cull G, et al.
Blood Adv
. 2024 Feb;
8(7):1639-1650.
PMID: 38315878
The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on...
6.
Lew T, Bennett R, Lin V, Whitechurch A, Handunnetti S, Marlton P, et al.
Blood Adv
. 2024 Jan;
8(6):1439-1443.
PMID: 38231032
No abstract available.
7.
Anderson M, Bennett R, Badoux X, Best G, Chia N, Cochrane T, et al.
Intern Med J
. 2023 Sep;
53(9):1678-1691.
PMID: 37743239
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The...
8.
Loo S, Roberts A, Anstee N, Kennedy G, He S, Schwarer A, et al.
Blood
. 2023 Aug;
142(23):1960-1971.
PMID: 37647654
Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising outcomes have been reported for...
9.
Dimopoulos M, Opat S, DSa S, Jurczak W, Lee H, Cull G, et al.
J Clin Oncol
. 2023 Jul;
41(33):5099-5106.
PMID: 37478390
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN....
10.
Lasater E, Amin D, Bannerji R, Mali R, Barrett K, Rys R, et al.
Am J Hematol
. 2023 Jan;
98(3):449-463.
PMID: 36594167
The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro-survival BCL-2 protein family member MCL-1 as a resistance factor for...